Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699429 | 0.88 | CYP1A2 (0.51) | CYP1A2 | |
| SCHEMBL16798442 | 0.87 | CTSS (0.44) | PPARGPPARACYP1A2MME | |
| SCHEMBL16798383 | 0.86 | LDHA (0.51) | KMT2APPARGPPARA | |
| SCHEMBL23699431 | 0.84 | MAOB (0.42) | PPARAMAOBMME | |
| SCHEMBL16798266 | 0.83 | PPARA (0.40) | PPARGPPARA | |
| SCHEMBL12980047 | 0.80 | PPARA (0.39) | KMT2APPARGPPARACYP1A2CYP2C9 | |
| SCHEMBL5803685 | 0.79 | ADORA1 (0.48) | PPARGPPARAMAOBCYP3A4CYP1A2 | |
| SCHEMBL5322873 | 0.79 | ADORA1 (0.48) | PPARGPPARAMAOBCYP3A4CYP1A2 | |
| SCHEMBL6557867 | 0.79 | ADORA1 (0.48) | PPARGPPARAMAOBCYP3A4CYP1A2 | |
| SCHEMBL31622222 | 0.79 | POLB (0.44) | KMT2APPARGPPARACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10278975-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3077401-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015085007-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-20150182537-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-10278975-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KMT2A 2568/4885PPARG 4471/4885EPHX2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.